ATLAS Market profile
Menu
Atlas · Symbols · Stocks & Shares · NRC

Atlas market file · Equity · United States

Nrc HealthNRC

Last close
20.34
Change
+4.47%
96-bar range
14.71 – 23.68
As of
7 Aug 2026

Nrc Health is a services-commercial physical & biological research issuer listed as NRC on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.

Identity
Nasdaq Trader
Chart rail
TradingView
File state
Public profile
Atlas chart snapshot NASDAQ:NRC

Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.

23.949121.572119.19516.81814.440923 Mar01 Jun07 Aug

up candle   down candle

Latest close20.34
Day change+4.47%
Window high23.68
Window low14.71
96-bar change+16.16%
SnapshotDaily · 96 bars
As of2026-08-07 13:30 UTC

Weekly outlook: the last 104 weekly closes (-7.04% over the window).

23.290410.049619 Aug07 Aug

Source rail: Yahoo Finance chart API (NRC). This dated snapshot is the crawlable Atlas reference.

Live market viewTradingView · provider feed Open view

Open the attributed TradingView market view for NRC. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.

Loading the attributed market view...

Open full TradingView chart ->

At a glance

NRC public profile

Company

Services-commercial physical & biological research issuer. Nrc Health is connected to current market context, cited company sources and its retained research file.

Market

Nrc Health trades as NRC on NASDAQ. Nrc Health (NRC) has a latest verified close of 20.34, up 4.47%, dated 7 Aug 2026.

Research

Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files NRC under USA Stocks and Healthcare & Medicine Stocks for browsing.

Institutional Market Wit ● Sourced Research File

NRC Health's latest 10-Q shows a company that sounds like a Silicon Prairie unicorn-$34.8 million in revenue, $5.6 million in operating income, and $7.2 million in operating cash flow for the quarter-but its balance sheet is more of a rust-belt fixer-upper, with $121.1 million in liabilities and just $2.5 million in cash at the end of March. The numbers are up from last year, but the gap between the glossy patient-experience brochures and the actual cash in the drawer is the kind of gap that makes you wonder which side of the "collaborative and integrated" promise is doing the walking. The 8-Ks and Form 4s from late June show directors approving amended equity awards like they're playing a board game where the goal is to keep the share count ticking...

Unlock 25 custom research runs/day, 104-week candle charts, PDF report downloads & 500-symbol watchlist.

Unlock Atlas Pro — £12/mo Open Free Workstation Run →
Daily answer

What changed for Nrc Health today

Open full report
NRC daily contextvalidated public digest14 source rail2026-08-07 02:40 UTC

NRC Health, the Nebraska-based healthcare-experience outfit, reported quarterly revenue of $34.8 million for the three months ending 31 March 2026, up from $33.6 million a year earlier, driven mainly by subscription-based services that let hospitals and clinics outsource the emotional labour of patient feedback to a dashboard. Operating income clocked in at $5.6 million, while operating cash flow was a healthier $7.2 million, giving the business enough oxygen to keep the lights on and the software licences renewed. The filings, however, read less like a growth story and more like a cash-flow tale, with the balance sheet sporting $121.1 million of liabilities against just $13.5 million of shareholders’ equity and a cash pile of $2.5 million that would struggle to cover a single quarter’s payroll if the subscription renewals stumbled. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/70487/000143774926015083/nrc20260331_10q.htm)

What NRC actually sells is a bundle of patient-experience software and advisory services marketed as a way to turn raw survey data into “clear action” for hospital boards that would rather not read 12,000 verbatim comments before lunch. The patient-experience platform promises lasting patient-provider relationships, while the advisory page promises expert advisors who will transform data into decisions. The gap between the marketing copy and the 10-Q’s admission that direct expenses rose to $13.6 million-mostly third-party software subscriptions and IT contractors-suggests the relationships may be built on rented code and gig labour rather than bespoke care. The company’s imagery leans hard on awards like “Best in KLAS,” but the only award the cash register recognises is the one that keeps the servers breathing. (source: NRC product pages, https://www.nrchealth.com/solutions/patient-experience/ and https://nrchealth.com/advisory-services/)

The company’s latest SEC submissions show a busy filing trail stack: an April 2026 8-K announcing amendments to equity awards for unnamed executives, followed by a flurry of Form 4s on 25 June 2026 that disclose director trades within the same week the board approved changes to prior awards. The filings do not say whether the award tweaks were repricings, retention sweeteners, or just the corporate version of a loyalty-card upgrade, but the timing is neat: when the cash balance is $2.5 million and the liabilities are north of $120 million, even a small adjustment to dilution can feel like a big story. The company’s weighted-average diluted share count sits at 21.9 million, and with EPS of $0.14 for the quarter, the arithmetic is plain: spread the $7.2 million operating cash flow across 21.9 million shares and you’re left wondering which line item is really doing the heavy lifting. (source: SEC EDGAR 10-Q, 8-K and Form 4s, https://www.sec.gov/Archives/edgar/data/70487/000143774926015083/nrc20260331_10q.htm)

For readers who like to chase charts, the SEC filings do not supply a pricing ticker or a TradingView route, so the only way to plot the stock’s mood is through the company’s own liquidity numbers and the board’s equity machinations. The cash balance of $2.5 million and the $1.8 million spent on property, plant, and equipment in the quarter suggest a company that is still investing in its own infrastructure while hoping the subscriptions keep rolling in. Meanwhile, the absence of any dividend or buyback language in the filings keeps the shareholder-return narrative on ice. If the next catalyst is a new product release or a customer win, the evidence so far offers no named press release or SEC filing to anchor it. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/70487/000143774926015083/nrc20260331_10q.htm)

The company’s own product pages are slick and award-decorated, but the filings do not connect the glossy messaging to concrete evidence of margin expansion or customer retention improvements. The 10-Q admits direct expenses rose on third-party software and contractor costs, which is corporate code for “we outsourced the hard yards,” and the board’s late-June equity tweaks read like an attempt to keep incentives aligned without admitting the cash runway is short. Until the next earnings release or an 8-K that names a customer contract or a product milestone, the file remains a study in how marketing and finance can inhabit parallel universes. (source: SEC EDGAR filings and product pages, https://www.sec.gov/Archives/edgar/data/70487/)

Sources & evidence · 10 links

This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.

Ticker
NRC
Exchange
NASDAQ
Sector
Us Public Equity Directory
Region
United States
Asset class
Equity
Directory source
Nasdaq Trader
SEC CIK
TradingView

NRC technical readout

Trend strength (ADX 14)
18.0
Average true range (ATR 14)
1.0943
ATR as % of price
4.90%
Volatility compression (ATR14/ATR50)
1.08x

Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.

Source authority

NRC evidence rails

Atlas uses the specific public rails available for NRC: SEC EDGAR, Nasdaq Trader, TradingView, FRED. Source names identify the public evidence trail; no partnership, sponsorship or endorsement is implied.

Sources & evidence · 5 rails

Open an Atlas research path on NRC

FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.

Open Atlas workstation ->
📄
Institutional Research PDF Available for NRC Verified 104-week candle chart, SEC filing evidence & risk register.
Download PDF
Atlas Pro

Keep NRC research in your Atlas archive

Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.

Checking Atlas access...

NRC FAQ

What is Nrc Health (NRC)?Nrc Health (NRC) has a latest verified close of 20.34, up 4.47%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks...

Nrc Health (NRC) has a latest verified close of 20.34, up 4.47%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.

What does Atlas show for NRC?Nrc Health (NRC) has a latest verified close of 20.34, up 4.47%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the...

Nrc Health (NRC) has a latest verified close of 20.34, up 4.47%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files NRC under USA Stocks and Healthcare & Medicine Stocks for browsing.

How often is the NRC page updated?The NRC public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...

The NRC public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.

Which sources does Atlas use for NRC?The NRC file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:NRC. SEC EDGAR provides the filing anchor for this issuer. The page separates verified...

The NRC file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:NRC. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.

Can Atlas run a full research brief on NRC?Yes. The workstation can open NRC, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.

Yes. The workstation can open NRC, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.

Is this NRC page investment advice?No. The NRC page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...

No. The NRC page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.

Methodology

This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.

Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.

Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →